|
|
专题 |
最后回覆 |
昵称 |
内容 |
无锡药明康德新药开发股份有限公司 |
2023-04-25T10:14 |
财经茄呢啡 |
药明康德(2359)今年首季新增客户超过310家,活跃客户数量超过6000家,全球各地的客户对公司的服务需求持续增长。随着全球患者对于药物的需求不断增长,客户对公司一体化CRDMO(合同研究、开发与生产)和CTDMO(合同测试、研发与生产)服务的需求持续增长,预计今年全年将实现5至7%的收入增长。 |
无锡药明康德新药开发股份有限公司 |
2022-03-23T23:49 |
财经茄呢啡 |
药明康德 去年收入约229.02亿元人币,按年增38.5%;利润约82.66亿元人币,按年增72.2%;经调整利润约51.31亿元,按年增41.1%;每股利润约1.75元,每10股派末期息5.174元,即每股0.5174元。 |
|
|
|
We've noticed you're using an ad blocker
We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.
To continue using 88iv.com, please allow this domain on your ad blocker.
We are thanksful for your decisive action.
This notice will be shown again every hour.
Close This Window